BioMarin Pharma (BMRN) Tops Q3 EPS by 15c, Offers Guidance

BioMarin Pharma (NASDAQ: BMRN) reported Q3 EPS of ($0.07), $0.15 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $391.7 million versus the consensus estimate of $367.09 million.

GUIDANCE:

BioMarin Pharma sees FY2018 revenue of $1.47-1.53 billion, versus the consensus of $1.51 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $59 at H.C. Wainwright
• Jack Henry (JKHY) Tops Q4 EPS by 13c
• Target (TGT) Tops Q2 EPS by $1.78, Beats on Revenue; Offers FY27 EPS Guidance